This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Merck Canada Inc., Merck Sharp + Dohme Corp.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 40 
1 out of 2,405 
Years Active: 2015
Title: **Vince J Colandrea: Innovator in HCV Therapeutics**
Introduction
Vince J Colandrea is an accomplished inventor based in North Brunswick, NJ, known for his significant contributions to the field of medicinal chemistry, particularly in the development of treatments for hepatitis C virus (HCV). His pioneering work has led to the filing of one patent that demonstrates his expertise and commitment to advancing health solutions.
Latest Patents
Colandrea holds a patent related to HCV NS3 protease inhibitors, specifically focused on compounds that feature a spirocyclic moiety. This invention not only highlights the potential therapeutic applications of these inhibitors but also encapsulates the synthesis methods for creating such compounds. His work is crucial, as it contributes to the fight against hepatitis C, a virus affecting millions globally.
Career Highlights
Throughout his career, Vince J Colandrea has made notable strides in pharmaceutical research, particularly during his tenure at respected institutions like Merck Sharp & Dohme Corporation and Merck Canada Inc. His roles at these organizations provided him with valuable experience and insight into the pharmaceutical industry, enabling him to pursue innovative solutions in healthcare.
Collaborations
Colandrea's career has been marked by fruitful collaborations with other professionals in the field. Notably, he has worked alongside Thomas A Bara and Sathesh P Bhat, whose combined expertise has likely enhanced the development and refinement of his inventions. These collaborations underscore the importance of teamwork in advancing scientific discovery.
Conclusion
Vince J Colandrea's work in developing HCV NS3 protease inhibitors showcases his talent and dedication to improving health outcomes. With his patent in hand and a history of collaboration with leading figures in the industry, Colandrea remains a significant contributor to the field of medicinal research, poised to inspire future innovations in the battle against hepatitis C.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile